Skip to main content

Table 2 Clinical correlations

From: Salivary psoriasin (S100A7) correlates with diffusion capacity of carbon monoxide in a large cohort of systemic sclerosis patients

Non-parametric correlations Psoriasin (µg/ml) Acral ulcers Skin ACA SCL70 DLCO Lung fibrosis (HRTC)
Rho Spearman
 Psoriasin (µg/ml)
  r 1.000 0.032 0.019 0.264 −0.150 0.186 0.117
  p value 0.0 0.730 0.860 0.002** 0.084 0.045* 0.199
  n 134 121 90 133 133 117 122
 Acral ulcers
  r 0.032 1.000 0.219 0.053 0.093 0.186 0.132
  p value 0.730 0.0 0.039* 0.566 0.311 0.053 0.161
  n 121 121 89 121 121 109 114
 Skin
  r 0.019 0.219 −0.128 0.089 0.256 0.095
  p value 0.860 0.039* 0.0 0.228 0.406 0.019* 0.389
  n 90 89 90 90 90 84 85
 ACA
  r 0.264 0.053 −0.128 1.000 −0.467 −0.164 −0.336
  p value 0.002** 0.566 0.228 0.0 0.000** 0.078 0.000**
  n 133 121 90 133 133 117 122
 SCL70
  r −0.150 0.093 0.089 0.467 1.000 0.265 0.350
  p value 0.084 0.311 0.406 0.000** 0.0 0.004** 0.000**
  n 133 121 90 133 133 117 122
 DLCO
  r 0.186 0.186 0.256 −0.164 0.265 1.000 0.451
  p value 0.045* 0.053 0.019* 0.078 0.004** 0.0 0.000**
  n 117 109 84 117 117 117 113
 Lung fibrosis (HRTC)
  r 0.117 0.132 0.095 0.336 0.350 0.451 1.000
  p value 0.199 0.161 0.389 0.000** 0.000** 0.000** 0.0
  n 122 114 85 122 122 113 122
  1. The significant correlations of psoriasin with clinical parameters are in italics
  2. r correlation coefficient, n number of subjects, DLCO diffusion capacity of carbon monoxide, HRCT high resolution computed tomography
  3. Statistical significance level: * p < 0.05
  4. ** p < 0.01